Jonah Feldman is an assistant editor for Targeted Oncology and Peers and Perspectives in Oncology.
ONC-392 Monotherapy Shows Efficacy in in Advanced Solid Tumors
The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.
World Neuroendocrine Cancer Day: New Targeted Therapies for NETs
Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed recent trials and advances in neuroendocrine cancer research in an interview with Targeted Oncology for World Neuroendocrine Cancer Day.
No Difference in Survival for Younger, Older Patients With Metastatic CRC
A recently published study has shown no difference in survival outcomes for patients under 50 with colorectal cancer, despite greater treatment intensity and physical fitness.
Nivolumab Plus Ipilimumab Prolongs Survival in Mesothelioma
In an interview with Targeted Oncology, Solange Peters, MD, discussed the significance of the 3-year follow-up analysis of the CheckMate 743 study of nivolumab/ipilimumab in mesothelioma.
Apalutamide Linked with Lower Risk of Death in Prostate Cancer
Neeraj Agarwal, MD, spoke with Targeted Oncology about the success of the TITAN and SPARTAN studies as well as its use in real-world prostate cancer populations.
Rebastinib/Paclitaxel Shows Efficacy in Platinum-Resistant Ovarian Cancer
In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the findings from a study of rebastinib plus paclitaxel and unmet needs in the ovarian cancer setting.